HR+, HER2- Early Breast Cancer Overview & Risk of Recurrence Video

This slide deck provides an overview of HR+,HER2- early breast cancer (EBC) including prognosis, clinical features, treatment, & risk of disease recurrence.

~20% of patients with HR+,HER2- EBC may progress to metastatic disease, commonly within a few years after primary treatment. This slide deck provides more details on the clinical & pathological factors that may affect the risk of recurrence in people with EBC.

This slide deck is intended to educate health care providers on factors that influence oral medication adherence & persistence, and provides tools, resources, and guidelines to help improve adherence for their patients.